Key Highlights
- Loss per share was USD 2.46 against an estimate of a USD 2.45 loss.
- Revenue was USD 2.0 million, with none in the prior-year quarter.
- Net loss was USD 38.73 million, compared with USD 35.26 million.
- Cash and cash equivalents were USD 199.47 million at September 30.
Inhibrx Biosciences (NASDAQ:INBX) reported a third quarter 2026 loss per share of USD 2.46, against an estimate of a USD 2.45 loss and a USD 2.28 loss in the third quarter of 2025. Revenue was USD 2.0 million, with none in the prior-year quarter.
The net loss was USD 38.73 million, compared with USD 35.26 million. The loss from operations was USD 31.74 million, compared with USD 33.81 million.
Operating Expenses
Research and development expenses were USD 25.97 million, compared with USD 28.54 million, and general and administrative expenses were USD 7.77 million, compared with USD 5.28 million. Total operating expenses were USD 33.74 million, compared with USD 33.81 million.
Interest expense was USD 8.75 million, compared with USD 3.18 million, and interest income was USD 1.75 million, compared with USD 1.78 million. Shares used in computing net loss per share were 15,720 thousand, compared with 15,478 thousand.
Nine-Month Results
For the nine months ended September 30, 2026, revenue was USD 2.0 million, compared with USD 1.3 million. The net loss was USD 108.82 million, compared with USD 107.22 million, and the net loss per share was USD 6.95, compared with USD 6.93.
Research and development expenses for the nine months were USD 75.08 million, compared with USD 87.68 million, and general and administrative expenses were USD 21.73 million, compared with USD 17.72 million. Total operating expenses were USD 96.81 million, compared with USD 105.40 million, and the loss from operations was USD 94.81 million, compared with USD 104.10 million. Interest expense for the nine months was USD 17.96 million, compared with USD 9.01 million, and interest income was USD 4.02 million, compared with USD 6.23 million.
Research Spending and Balance Sheet
The filing breaks Research and Development expense into personnel costs of USD 7.78 million, compared with USD 8.80 million, clinical trial costs of USD 8.65 million, compared with USD 11.85 million, and contract Manufacturing costs of USD 3.82 million, compared with USD 1.89 million. General and administrative personnel costs were USD 4.16 million, compared with USD 3.40 million, and other general and administrative costs were USD 3.61 million, compared with USD 1.88 million.
Cash and cash equivalents were USD 199.47 million, compared with USD 124.22 million at the prior Balance Sheet date, and total current Assets were USD 206.87 million, compared with USD 132.83 million. Prepaid expenses and other current assets were USD 7.20 million, compared with USD 8.44 million.
Total assets were USD 220.29 million, compared with USD 146.48 million, and total liabilities were USD 306.17 million, compared with USD 138.49 million. Total stockholders' Equity was a Deficit of USD 85.88 million, compared with equity of USD 7.99 million. Net cash used in Operating Activities for the nine months was USD 102.55 million, compared with USD 99.67 million.
Inhibrx Biosciences Q3 2026 Earnings: Key Takeaways
Inhibrx Biosciences reported a third quarter 2026 loss per share of USD 2.46 and a net loss of USD 38.73 million on revenue of USD 2.0 million. Cash and cash equivalents were USD 199.47 million at September 30, 2026.
_11_19_2026_19_19_13_574021.jpg)





Please wait processing your request...